Indian generic drug quality has been questioned recently by a number of U.S. doctors. The concern stems from FDA recalls and import bans.
A recent clinical trial found that 1 year of adjuvant imatinib was able to increase recurrence-free survival. Keep reading to learn more.
A recent nonrandomized study has shown that imatinib rechallenge impacted the survival rate for patients with advanced or metastatic gastrointestinal stromal tumor (GIST).
The Life Raft Group is pleased to announce the release of the first issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to GIST.